| The effect of alendronate (Fosamax) and implant surface on bone integration and remodeling in a canine model. | |
| | |
MedLine Citation:
|
PMID: 11745516 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Patients at high risk for osteoporosis and its associated morbidity, including postmenopausal women, are being pharmacologically managed to stabilize and improve bone mass. Alendronate sodium (Fosamax) is a commonly used antiresorptive agent effective in osteopenic women for reducing bone resorption, increasing bone density, and decreasing fracture incidence. With the increased incidence of alendronate-treated women who are undergoing hip replacement or fracture repair by prosthesis placement, data are needed to predict how alendronate affects host bone integration with uncemented surfaces. The aim of this study was to determine the effect of alendronate on new bone formation and attachment to implant surfaces in a normal and simulated estrogen-deficient, calcium-deficient canine model, using an implantable bone growth chamber. Alendronate did not affect host bone integration to surfaces commonly used in uncemented total joint arthroplasty, but there were significant differences dependent solely on the type of surface. |
| | |
Authors:
|
S R Frenkel; W L Jaffe; C D Valle; L Jazrawi; S Maurer; A Baitner; K Wright; D Sala; M Hawkins; P E Di Cesare |
Related Documents
:
|
19803906 - Ibandronate: once-monthly and intravenous dosing options for osteoporosis treatment. 8624566 - Osteoporosis and its relationship to oral bone loss. 7981986 - Genetics of osteoporosis. 16908396 - What is new in the treatment of steroid-induced osteoporosis? 19803906 - Ibandronate: once-monthly and intravenous dosing options for osteoporosis treatment. 6766616 - Anterior oblique projection in radiography of the traumatized shoulder. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of biomedical materials research Volume: 58 ISSN: 0021-9304 ISO Abbreviation: J. Biomed. Mater. Res. Publication Date: 2001 |
Date Detail:
|
Created Date: 2001-12-17 Completed Date: 2002-03-12 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0112726 Medline TA: J Biomed Mater Res Country: United States |
Other Details:
|
Languages: eng Pagination: 645-50 Citation Subset: IM |
Copyright Information:
|
Copyright 2001 John Wiley & Sons, Inc. |
Affiliation:
|
Musculoskeletal Research Center and Department of Orthopaedic Surgery, New York University Hospital for Joint Diseases, New York, New York 10003, USA. sally.frenkel@excite.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alendronate
/
pharmacology* Animals Arthroplasty, Replacement, Hip* Bone Plates Bone Remodeling / drug effects* Disease Models, Animal Dogs Female Femur / surgery*, ultrastructure Humans Implants, Experimental* Microscopy, Electron, Scanning Osseointegration / drug effects* Osteolysis / drug therapy Osteoporosis, Postmenopausal / drug therapy Ovariectomy Prosthesis Failure Stress, Mechanical Surface Properties |
| Chemical | |
Reg. No./Substance:
|
66376-36-1/Alendronate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Early dissolution of a morsellised impacted silicate-free bioactive glass in metaphyseal defects.
Next Document: Surface and biological evaluation of hydroxyapatite-based coatings on titanium deposited by differen...